Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin

被引:9
|
作者
Yang, Emily Y. [1 ]
Howard, Grant R. [2 ]
Brock, Amy [2 ,3 ,4 ]
Yankeelov, Thomas E. [1 ,2 ,3 ,5 ,6 ,7 ]
Lorenzo, Guillermo [1 ,8 ]
机构
[1] Univ Texas Austin, Oden Inst Computat Engn & Sci, Austin, TX 78712 USA
[2] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA
[3] Univ Texas Austin, Dell Med Sch, Livestrong Canc Inst, Austin, TX 78712 USA
[4] Univ Texas Austin, Interdisciplinary Life Sci Program, Austin, TX 78712 USA
[5] Univ Texas Austin, Dept Diagnost Med, Austin, TX 78712 USA
[6] Univ Texas Austin, Dept Oncol, Austin, TX 78712 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX 77030 USA
[8] Univ Pavia, Dept Civil Engn & Architecture, Pavia, Italy
基金
美国国家卫生研究院;
关键词
mathematical oncology; mathematical modeling; population dynamics; chemotherapy; drug resistance; breast cancer; time-resolved microscopy; DRUG-RESISTANCE; TUMOR HETEROGENEITY; DOSE-DENSE; NEOADJUVANT THERAPY; RANDOMIZED-TRIAL; LOGISTIC MODEL; CHEMOTHERAPY; MECHANISMS; SCHEDULE; SURVIVAL;
D O I
10.3389/fmolb.2022.972146
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development of chemoresistance remains a significant cause of treatment failure in breast cancer. We posit that a mathematical understanding of chemoresistance could assist in developing successful treatment strategies. Towards that end, we have developed a model that describes the cytotoxic effects of the standard chemotherapeutic drug doxorubicin on the MCF-7 breast cancer cell line. We assume that treatment with doxorubicin induces a compartmentalization of the breast cancer cell population into surviving cells, which continue proliferating after treatment, and irreversibly damaged cells, which gradually transition from proliferating to treatment-induced death. The model is fit to experimental data including variations in drug concentration, inter-treatment interval, and number of doses. Our model recapitulates tumor cell dynamics in all these scenarios (as quantified by the concordance correlation coefficient, CCC > 0.95). In particular, superior tumor control is observed with higher doxorubicin concentrations, shorter inter-treatment intervals, and a higher number of doses (p < 0.05). Longer inter-treatment intervals require adapting the model parameterization after each doxorubicin dose, suggesting the promotion of chemoresistance. Additionally, we propose promising empirical formulas to describe the variation of model parameters as functions of doxorubicin concentration (CCC > 0.78). Thus, we conclude that our mathematical model could deepen our understanding of the cytotoxic effects of doxorubicin and could be used to explore practical drug regimens achieving optimal tumor control.
引用
收藏
页数:21
相关论文
共 50 条
  • [31] Combination of tanshinone IIA and doxorubicin possesses synergism and attenuation effects on doxorubicin in the treatment of breast cancer
    Li, Kun
    Liu, Wensu
    Zhao, Qian
    Wu, Chunxia
    Fan, Chenxing
    Lai, Hong
    Li, Shizheng
    PHYTOTHERAPY RESEARCH, 2019, 33 (06) : 1658 - 1669
  • [32] Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors
    Sawasdee, Nunghathai
    Wattanapanitch, Methichit
    Thongsin, Nontaphat
    Phanthaphol, Nattaporn
    Chiawpanit, Chutipa
    Thuwajit, Chanitra
    Yenchitsomanus, Pa-Thai
    Panya, Aussara
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2022, 49 (03)
  • [33] Population Dynamics of Mitochondria in Cells: A Minimal Mathematical Model
    Kornick, Kellianne
    Bogner, Brandon
    Sutter, Leo
    Das, Moumita
    FRONTIERS IN PHYSICS, 2019, 7
  • [34] Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy
    Kirshner, J
    Hatch, M
    Hennessy, DD
    Fridman, M
    Tannous, RE
    ONCOLOGIST, 2004, 9 (01) : 25 - 32
  • [35] Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line
    AbuHammad, Shatha
    Zihlif, Malek
    GENOMICS, 2013, 101 (04) : 213 - 220
  • [36] Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: Preliminary results
    Hardenbergh, PH
    Munley, MT
    Bentel, GC
    Kedem, R
    Borges-Neto, S
    Hollis, D
    Prosnitz, LR
    Marks, LB
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (04): : 1023 - 1028
  • [37] Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells
    Manandhar, Sarala
    Kim, Chang-Gu
    Lee, Sun-Hee
    Kang, Soo Hyun
    Basnet, Nikita
    Lee, You Mie
    ONCOTARGET, 2017, 8 (41) : 70521 - 70537
  • [38] Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population dynamics model
    Pasquier, Jennifer
    Magal, Pierre
    Boulange-Lecomte, Celine
    Webb, Glenn
    Le Foll, Frank
    BIOLOGY DIRECT, 2011, 6
  • [39] Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin
    Chen, Guo-Qing
    Zhao, Zhi-Wei
    Zhou, Hong-Ying
    Liu, Yuan-Jie
    Yang, Hui-Jun
    MEDICAL ONCOLOGY, 2010, 27 (02) : 406 - 415
  • [40] Anti-cancer effects of Rhizoma Curcumae against doxorubicin-resistant breast cancer cells
    Zhong, Zhangfeng
    Yu, Haibing
    Wang, Shengpeng
    Wang, Yitao
    Cui, Liao
    CHINESE MEDICINE, 2018, 13